🎉 M&A multiples are live!
Check it out!

Zevra Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Zevra Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Zevra Therapeutics Overview

About Zevra Therapeutics

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.


Founded

2006

HQ

United States of America
Employees

59

Website

zevra.com

Financials

LTM Revenue $41.3M

LTM EBITDA -$66.1M

EV

$369M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Zevra Therapeutics Financials

Zevra Therapeutics has a last 12-month revenue of $41.3M and a last 12-month EBITDA of -$66.1M.

In the most recent fiscal year, Zevra Therapeutics achieved revenue of $23.6M and an EBITDA of -$76.4M.

Zevra Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Zevra Therapeutics valuation multiples based on analyst estimates

Zevra Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $27.5M $23.6M XXX XXX XXX
Gross Profit $10.1M $24.5M XXX XXX XXX
Gross Margin 37% 104% XXX XXX XXX
EBITDA -$43.5M -$76.4M XXX XXX XXX
EBITDA Margin -159% -324% XXX XXX XXX
Net Profit -$41.5M -$46.0M XXX XXX XXX
Net Margin -151% -195% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Zevra Therapeutics Stock Performance

As of April 15, 2025, Zevra Therapeutics's stock price is $7.

Zevra Therapeutics has current market cap of $378M, and EV of $369M.

See Zevra Therapeutics trading valuation data

Zevra Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$369M $378M XXX XXX XXX XXX $-1.75

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Zevra Therapeutics Valuation Multiples

As of April 15, 2025, Zevra Therapeutics has market cap of $378M and EV of $369M.

Zevra Therapeutics's trades at 8.9x LTM EV/Revenue multiple, and -5.6x LTM EBITDA.

Analysts estimate Zevra Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Zevra Therapeutics and 10K+ public comps

Zevra Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $369M XXX XXX XXX
EV/Revenue 15.6x XXX XXX XXX
EV/EBITDA -4.8x XXX XXX XXX
P/E -3.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Zevra Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Zevra Therapeutics Valuation Multiples

Zevra Therapeutics's NTM/LTM revenue growth is 159%

Zevra Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.7M for the same period.

Over next 12 months, Zevra Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Zevra Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Zevra Therapeutics and other 10K+ public comps

Zevra Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -14% XXX XXX XXX XXX
EBITDA Margin -324% XXX XXX XXX XXX
EBITDA Growth 75% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -164% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $1.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 178% XXX XXX XXX XXX
Opex to Revenue 437% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Zevra Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Zevra Therapeutics M&A and Investment Activity

Zevra Therapeutics acquired  XXX companies to date.

Last acquisition by Zevra Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Zevra Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Zevra Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Zevra Therapeutics

When was Zevra Therapeutics founded? Zevra Therapeutics was founded in 2006.
Where is Zevra Therapeutics headquartered? Zevra Therapeutics is headquartered in United States of America.
How many employees does Zevra Therapeutics have? As of today, Zevra Therapeutics has 59 employees.
Who is the CEO of Zevra Therapeutics? Zevra Therapeutics's CEO is Mr. Neil F. McFarlane, M.S..
Is Zevra Therapeutics publicy listed? Yes, Zevra Therapeutics is a public company listed on NAS.
What is the stock symbol of Zevra Therapeutics? Zevra Therapeutics trades under ZVRA ticker.
When did Zevra Therapeutics go public? Zevra Therapeutics went public in 2015.
Who are competitors of Zevra Therapeutics? Similar companies to Zevra Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Zevra Therapeutics? Zevra Therapeutics's current market cap is $378M
What is the current revenue of Zevra Therapeutics? Zevra Therapeutics's last 12-month revenue is $41.3M.
What is the current EBITDA of Zevra Therapeutics? Zevra Therapeutics's last 12-month EBITDA is -$66.1M.
What is the current EV/Revenue multiple of Zevra Therapeutics? Current revenue multiple of Zevra Therapeutics is 8.9x.
What is the current EV/EBITDA multiple of Zevra Therapeutics? Current EBITDA multiple of Zevra Therapeutics is -5.6x.
What is the current revenue growth of Zevra Therapeutics? Zevra Therapeutics revenue growth between 2023 and 2024 was -14%.
Is Zevra Therapeutics profitable? Yes, Zevra Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.